Patents by Inventor Saulius Butenas

Saulius Butenas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8574849
    Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: November 5, 2013
    Assignee: The University of Vermont and State Agriculture College
    Inventors: Kenneth G. Mann, Saulius Butenas, Anetta Undas
  • Publication number: 20100261198
    Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.
    Type: Application
    Filed: October 3, 2008
    Publication date: October 14, 2010
    Applicant: The University of Vermont and State Agriculture College, College of Medicine
    Inventors: Kenneth G. Mann, Saulius Butenas, Anetta Undas
  • Publication number: 20090325203
    Abstract: The invention provides assays for detecting and quantitating tissue factor and factor VIIa in simple and complex biological systems. The assays are performed by detecting and/or measuring the tissue factor cofactor activity and factor VIIa enzymatic activity using aminonaphthalene-based fluorogenic substrates.
    Type: Application
    Filed: September 4, 2009
    Publication date: December 31, 2009
    Inventors: Richard J. Jenny, Saulius Butenas
  • Patent number: 7604932
    Abstract: The invention provides assays for detecting and quantitating tissue factor and factor VIIa in simple and complex biological systems. The assays are performed by detecting and/or measuring the tissue factor cofactor activity and factor VIIa enzymatic activity using aminonapthalene-based fluorogenic substrates.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: October 20, 2009
    Assignee: Haematologic Technologies, Inc.
    Inventors: Richard J. Jenny, Saulius Butenas
  • Publication number: 20060148022
    Abstract: The invention provides assays for detecting and quantitating tissue factor and factor VIIa in simple and complex biological systems. The assays are performed by detecting and/or measuring the tissue factor cofactor activity and factor VIIa enzymatic activity using aminonapthalene-based fluorogenic substrates.
    Type: Application
    Filed: November 6, 2003
    Publication date: July 6, 2006
    Inventors: Richard Jenny, Saulius Butenas
  • Patent number: 7015193
    Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: March 21, 2006
    Assignee: University of Vermont
    Inventors: Saulius Butenas, Kenneth G. Mann, Kathleen Brummel
  • Patent number: 6566493
    Abstract: Compounds of the following formula are disclosed, wherein R1 is a peptide and R2 is an amino acid or peptide as disclosed herein: The compounds are inhibitors of activated protein C.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: May 20, 2003
    Assignee: The University of Vermont
    Inventors: Saulius Butenas, Kenneth G. Mann
  • Publication number: 20030050225
    Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.
    Type: Application
    Filed: April 19, 2002
    Publication date: March 13, 2003
    Inventors: Saulius Butenas, Kenneth G. Mann
  • Patent number: 5399487
    Abstract: The present invention encompasses compounds of formula I: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof; wherein R.sub.1 is hydrogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl;R.sub.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl; orNR.sub.1 R.sub.2 forms a nitrogen heterocycle; andR.sub.3 is hydrogen, an amino acid or a peptide residue.These compounds may be employed as substrates in assays for determining proteolytic enzyme activity or as enzyme inhibitors. The invention also encompasses methods for determining proteolytic enzyme activity using the compounds of formula I.
    Type: Grant
    Filed: March 4, 1993
    Date of Patent: March 21, 1995
    Assignee: Haematologic Technologies, Inc.
    Inventors: Saulius Butenas, Jeffrey H. Lawson, Kenneth G. Mann